Skip to main content

Table 4 Global tolerability assessed by patients/their guardians and blinded investigator via 4-point VRS

From: High efficacy of a dimeticone-based pediculicide following a brief application: in vitro assays and randomized controlled investigator-blinded clinical trial

 

Patient

Investigator

Dimeticone

Permethrin

Dimeticone

Permethrin

Very good

41/49 (85.4%)

41/48 (85.4%)

48/49 (98.0%)

44/48 (91.7%)

Good

6/49 (12.2%)

6/48 (12.5%)

–

4/48 (8.3%)

Moderate

2/49 (4.1%)

1/48 (2.1%)

1/49 (2.0%)

–

Poor

–

–

–

–

Back to article page

BMC Dermatology

ISSN: 1471-5945

Contact us